

Hai-Bo Wang,\* Jia-Hui Chen,  
Yue-Qing Pu and Jin-Tang WangDepartment of Applied Chemistry, College of  
Science, Nanjing University of Technology,  
Xinmofan Road No. 5 Nanjing, Nanjing  
210009, People's Republic of ChinaCorrespondence e-mail:  
wanghaibo@njut.edu.cn

## Key indicators

Single-crystal X-ray study  
 $T = 293$  K  
Mean  $\sigma(\text{C}-\text{C}) = 0.003$  Å  
 $R$  factor = 0.041  
 $wR$  factor = 0.142  
Data-to-parameter ratio = 14.8For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.

## Methyl 2-[[3-(4-methylsulfanyl)phenyl]-1,2,4-oxadiazol-5-yl]methoxyphenylacetate

The title compound,  $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_4\text{S}$ , was synthesized by the reaction of methyl (2-hydroxyphenyl)acetate and 3-(4-methylthio)phenyl-5-chloromethyl-1,2,4-oxadiazole. The structure exhibits intermolecular  $\text{C}-\text{H}\cdots\text{O}$  hydrogen bonds and  $\text{C}-\text{H}\cdots\pi$  interactions.

Received 11 October 2004

Accepted 20 October 2004

Online 30 October 2004

## Comment




1,2,4-Oxadiazole derivatives are of great interest because of their biological properties. Some derivatives of 1,2,4-oxadiazoles have intrinsic analgesic (Terashita *et al.*, 2002), anti-inflammatory (Nicolaidis *et al.*, 1998) and antipicornaviral (Romero, 2001) properties and show high efficacy as agonists [*e.g.* for muscarinic (Macor *et al.*, 1996), adrenergic (Quagliato & Andrae, 2002) and 5-hydroxytryptamine (Gur *et al.*, 2001)] and antagonists [*e.g.* for angiotensin (Naka & Kubo, 1999) and adhesion (Jurazyk *et al.*, 1997)] for different receptors. We report here the crystal structure of the title compound, (I).The molecular structure of (I) is shown in Fig. 1 and bond lengths, angles and torsion angles are given in Table 1. In the crystal structure, molecules are linked by  $\text{C}-\text{H}\cdots\text{O}$  hydrogen bonds (Table 2). There are also  $\text{C}-\text{H}\cdots\pi$  interactions in the crystal structure (Table 2 and Fig. 3).

Figure 1

A view of the molecular structure of (I). Displacement ellipsoids are drawn at the 30% probability level.



**Figure 2**  
The short C—H...O contact (dashed line) in the crystal structure of (I).

## Experimental

Methyl (2-hydroxyphenyl)acetate (20 mmol) was dissolved in acetone (20 ml) and potassium carbonate (30 mmol) was added in one portion. 3-[4-Methylsulfonyl]phenyl]-5-chloromethyl-1,2,4-oxadiazole (20 mmol) in acetone (20 ml) was added to this mixture. The resulting mixture was refluxed for 6 h, then concentrated under reduced pressure to afford crude compound (I). Pure compound (I) was obtained by crystallization from ethyl acetate (m.p. 359–360 K). Crystals of (I) suitable for X-ray diffraction were obtained by slow evaporation of an ethanol solution.  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  7.98–8.00 (*m*, 2H), 7.31–7.32 (*m*, 2H), 7.23–7.27 (*m*, 2H), 6.98–7.03 (*m*, 2H), 5.34 (*s*, 2H), 3.73 (*s*, 2H), 3.69 (*s*, 3H), 3.52 (*s*, 3H).

### Crystal data


$\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_4\text{S}$	$Z = 2$
$M_r = 370.41$	$D_x = 1.373 \text{ Mg m}^{-3}$
Triclinic, $P\bar{1}$	Mo $K\alpha$ radiation
$a = 8.3580$ (17) Å	Cell parameters from 25 reflections
$b = 10.522$ (2) Å	$\theta = 10\text{--}13^\circ$
$c = 10.581$ (2) Å	$\mu = 0.21 \text{ mm}^{-1}$
$\alpha = 90.13$ (3) $^\circ$	$T = 293$ (2) K
$\beta = 102.08$ (3) $^\circ$	Block, colourless
$\gamma = 99.73$ (3) $^\circ$	$0.4 \times 0.3 \times 0.3 \text{ mm}$
$V = 896.1$ (3) Å $^3$	

### Data collection

Nonius CAD-4 diffractometer	$\theta_{\text{max}} = 26.0^\circ$
$\omega/2\theta$ scans	$h = 0 \rightarrow 10$
Absorption correction: none	$k = -12 \rightarrow 12$
3752 measured reflections	$l = -13 \rightarrow 12$
3499 independent reflections	3 standard reflections
2763 reflections with $I > 2\sigma(I)$	every 200 reflections
$R_{\text{int}} = 0.021$	intensity decay: none

### Refinement

Refinement on $F^2$	$w = 1/[\sigma^2(F_o^2) + (0.1P)^2 + 0.35P]$
$R[F^2 > 2\sigma(F^2)] = 0.041$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.142$	$(\Delta\sigma)_{\text{max}} = 0.014$
$S = 0.91$	$\Delta\rho_{\text{max}} = 0.32 \text{ e \AA}^{-3}$
3499 reflections	$\Delta\rho_{\text{min}} = -0.21 \text{ e \AA}^{-3}$
236 parameters	Extinction correction: <i>SHELXL97</i>
H-atom parameters constrained	Extinction coefficient: 0.036 (5)



**Figure 3**  
The C—H... $\pi$  interactions in (I), shown as dashed lines.

**Table 1**

Selected geometric parameters (Å,  $^\circ$ ).

S—C2	1.757 (2)	O4—C19	1.442 (3)
S—C1	1.782 (3)	N1—C8	1.304 (3)
O1—C9	1.334 (2)	N2—C8	1.380 (2)
O1—N1	1.416 (2)	N2—C9	1.292 (2)
O2—C10	1.415 (2)	C5—C8	1.468 (3)
O2—C11	1.378 (2)	C9—C10	1.496 (3)
O3—C18	1.200 (2)	C16—C17	1.505 (3)
O4—C18	1.339 (2)	C17—C18	1.504 (2)
C2—S—C1	104.11 (12)	N2—C9—C10	130.83 (18)
C9—O1—N1	106.07 (14)	O1—C9—C10	115.29 (16)
C11—O2—C10	118.04 (15)	O2—C10—C9	113.34 (15)
C18—O4—C19	115.95 (17)	O2—C11—C12	123.99 (17)
C8—N1—O1	103.23 (16)	O2—C11—C16	115.13 (16)
C9—N2—C8	102.45 (16)	C15—C16—C17	120.89 (17)
C7—C2—S	117.43 (17)	C11—C16—C17	120.87 (17)
C4—C5—C8	120.43 (18)	C18—C17—C16	113.25 (15)
N1—C8—N2	114.38 (17)	O3—C18—O4	122.65 (18)
N1—C8—C5	122.09 (18)	O3—C18—C17	126.41 (18)
N2—C8—C5	123.50 (17)	O4—C18—C17	110.87 (16)
N2—C9—O1	113.87 (17)		
C9—O1—N1—C8	0.2 (2)	C9—N2—C8—N1	0.4 (2)
N1—O1—C9—C10	178.57 (17)	C9—N2—C8—C5	-177.86 (18)
N1—O1—C9—N2	0.1 (2)	C8—N2—C9—O1	-0.3 (2)
C11—O2—C10—C9	-80.0 (2)	C8—N2—C9—C10	-178.5 (2)
C10—O2—C11—C16	-171.15 (17)	C6—C5—C8—N2	-8.0 (3)
C10—O2—C11—C12	9.2 (3)	C4—C5—C8—N1	170.72 (19)
C19—O4—C18—C17	-179.3 (2)	C6—C5—C8—N1	173.9 (2)
C19—O4—C18—O3	-2.3 (3)	C4—C5—C8—N1	-7.4 (3)
O1—N1—C8—C5	177.94 (17)	N2—C9—C10—O2	-8.8 (3)
O1—N1—C8—N2	-0.3 (2)	O1—C9—C10—O2	173.01 (17)

**Table 2**  
Hydrogen-bonding geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
C12—H12A $\cdots$ O3 <sup>i</sup>	0.93	2.43	3.257 (3)	148
C10—H10A $\cdots$ Cg2 <sup>ii</sup>	0.97	2.77	3.58	142
C10—H10B $\cdots$ Cg3 <sup>i</sup>	0.97	2.65	3.43	138
C17—H17B $\cdots$ Cg3 <sup>iii</sup>	0.97	2.85	3.42	118

Symmetry codes: (i)  $2-x, -1-y, 3-z$ ; (ii)  $1-x, -1-y, 2-z$ ; (iii)  $1-x, -1-y, 3-z$ . Notes: Cg2 is the centroid of atoms C2–C7 and Cg3 is the centroid of atoms C11–C16.

All H atoms were bonded to the C atoms were placed geometrically, with C–H = 0.93–0.97 Å, and included in the refinement in the riding model approximation, with  $U_{iso}(H) = 1.2$  or  $1.5U_{eq}$  of the carrier atom.

Data collection: *CAD-4 Software* (Enraf–Nonius, 1989); cell refinement: *CAD-4 Software*; data reduction: *XCAD4* (Harms & Wocadlo, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97*

(Sheldrick, 1997); molecular graphics: *SHELXTL* (Siemens, 1996); software used to prepare material for publication: *SHELXTL*.

## References

- Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.
- Gur, E., Dremencov, E., Lerer, B. & Newman, M. E. (2001). *Eur. J. Pharmacol.* **411**, 115–122.
- Harms, K. & Wocadlo, S. (1995). *XCAD4*. University of Marburg, Germany.
- Juraszyk, H., Gante, J., Wurziger, H., Bernotat-Danielowski, S. & Melzer, G. (1997). PCT Int. Appl. No. 9744333.
- Macor, J. E., Ordway, T., Smith, R. L., Verhoest, P. R. & Mack, R. A. (1996). *J. Org. Chem.* **61**, 3228–3229.
- Naka, T. & Kubo, K. (1999). *Curr. Pharm. Des.* **5**, 453–472.
- Nicolaides, D. N., Fylaktakidou, K. C., Litinas, K. E. & Hadjipavlou-Litina, D. (1998). *Eur. J. Med. Chem.* **33**, 715–724.
- Quagliato, D. A. & Andrae, P. M. (2002). PCT Int. Appl. No. 0206250.
- Romero, J. R. (2001). *Expert Opin. Invest. Drugs*, **10**, 369–379.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Siemens (1996). *SHELXTL*. Version 5.06. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
- Terashita, Z., Naruo, K. & Morimoto, S. (2002). PCT Int. Appl. No. 0260439.